OPKO Health Inc
OPK1.300USD
-0.010-0.76%
收盤 12/24, 13:00（美東）報價延遲15分鐘
999.31M總市值
虧損本益比TTM
關於 OPKO Health Inc 公司
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
OPKO Health Inc簡介
公司代碼OPK
公司名稱OPKO Health Inc
上市日期Nov 02, 1995
CEOCruz (Tony F)
員工數量2997
證券類型Ordinary Share
年結日Nov 02
公司地址- -
城市- -
上市交易所NASDAQ OMX - NASDAQ BASIC
國家- -
郵編- -
電話- -
網址- -
公司代碼OPK
上市日期Nov 02, 1995
CEOCruz (Tony F)
OPKO Health Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Dr. Alice Lin-Tsing Yu, M.D., Ph.D.
Independent Director
Independent Director
66.49K
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Dr. Tony F. Cruz, Ph.D.
Dr. Tony F. Cruz, Ph.D.
Chief Executive Officer, Transition Therapeutics, Inc
Chief Executive Officer, Transition Therapeutics, Inc
--
--
Dr. Roger J. Medel, M.D.
Dr. Roger J. Medel, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Jane H. Hsiao, Ph.D.
Dr. Jane H. Hsiao, Ph.D.
Vice Chairman of the Board, Chief Technical Officer
Vice Chairman of the Board, Chief Technical Officer
33.13M
--
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Mr. Steven D. (Steve) Rubin, Esq., J.D.
Executive Vice President - Administration, Director
Executive Vice President - Administration, Director
6.19M
-6.60%
Mr. John A. Paganelli
Mr. John A. Paganelli
Independent Director
Independent Director
393.51K
--
Mr. Adam E. Logal
Mr. Adam E. Logal
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
179.16K
-70.95%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
103.33K
--
Dr. Elias A. Zerhouni, M.D.
Dr. Elias A. Zerhouni, M.D.
President, Vice Chairman of the Board
President, Vice Chairman of the Board
89.60K
-84.80%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Health Insurers
58.48M
57.84%
Client Payers
23.17M
22.92%
Government Payers
17.10M
16.92%
Patients
2.35M
2.33%
地區USD
名稱
營收
佔比
United States
114.88M
73.26%
Chile
16.00M
15.83%
Ireland
11.74M
11.61%
Spain
6.72M
6.65%
Mexico
6.30M
6.23%
其他
-54.55M
-13.59%
業務
地區
業務USD
名稱
營收
佔比
Health Insurers
58.48M
57.84%
Client Payers
23.17M
22.92%
Government Payers
17.10M
16.92%
Patients
2.35M
2.33%
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Frost Gamma Investments Trust
28.98%
Rubric Capital Management LP
6.23%
Holbrook (Bruce C)
5.26%
The Vanguard Group, Inc.
4.88%
Hsiao (Jane H)
4.32%
其他
50.34%
持股股東
持股股東
佔比
Frost Gamma Investments Trust
28.98%
Rubric Capital Management LP
6.23%
Holbrook (Bruce C)
5.26%
The Vanguard Group, Inc.
4.88%
Hsiao (Jane H)
4.32%
其他
50.34%
股東類型
持股股東
佔比
Corporation
38.14%
Investment Advisor
12.40%
Individual Investor
10.57%
Hedge Fund
7.37%
Investment Advisor/Hedge Fund
5.49%
Research Firm
0.48%
Bank and Trust
0.21%
Pension Fund
0.14%
Family Office
0.05%
其他
25.15%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
457
208.31M
27.13%
-63.18M
2025Q2
472
618.23M
77.88%
-578.48K
2025Q1
498
645.32M
88.41%
+25.74M
2024Q4
501
573.04M
84.80%
-7.63M
2024Q3
497
562.18M
81.01%
-12.00M
2024Q2
501
553.77M
79.70%
+8.59M
2024Q1
492
531.83M
76.52%
-21.84M
2023Q4
493
533.01M
69.65%
+31.42M
2023Q3
496
529.79M
69.24%
+23.70M
2023Q2
502
536.53M
70.13%
+25.42M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Frost Gamma Investments Trust
220.16M
27.74%
+360.00K
+0.16%
Sep 30, 2025
Rubric Capital Management LP
47.79M
6.02%
-915.40K
-1.88%
Jun 30, 2025
Holbrook (Bruce C)
40.38M
5.09%
--
--
Feb 24, 2025
The Vanguard Group, Inc.
38.16M
4.81%
+8.74M
+29.70%
Jun 30, 2025
Hsiao (Jane H)
33.13M
4.17%
--
--
Apr 02, 2025
Frost Group, L.L.C.
30.13M
3.8%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
28.22M
3.55%
+3.45M
+13.93%
Jun 30, 2025
GJN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
EGN 2021 Trust
19.91M
2.51%
--
--
Feb 24, 2025
Geode Capital Management, L.L.C.
10.42M
1.31%
+2.00M
+23.68%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.53%
State Street SPDR S&P Health Care Services ETF
0.46%
VanEck Israel ETF
0.14%
Humankind US Stock ETF
0.1%
iShares U.S. Healthcare Providers ETF
0.1%
Goldman Sachs Innovate Equity ETF
0.06%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
iShares Biotechnology ETF
0.04%
Invesco RAFI US 1500 Small-Mid ETF
0.04%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0.53%
State Street SPDR S&P Health Care Services ETF
佔比0.46%
VanEck Israel ETF
佔比0.14%
Humankind US Stock ETF
佔比0.1%
iShares U.S. Healthcare Providers ETF
佔比0.1%
Goldman Sachs Innovate Equity ETF
佔比0.06%
iShares MSCI USA Small-Cap Min Vol Factor ETF
佔比0.05%
iShares Russell 2000 Value ETF
佔比0.04%
iShares Biotechnology ETF
佔比0.04%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.04%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
OPKO Health Inc的前五大股東是誰？
OPKO Health Inc的前五大股東如下：
Frost Gamma Investments Trust持有股份：220.16M佔總股份比例：27.74%。
Rubric Capital Management LP持有股份：47.79M佔總股份比例：6.02%。
Holbrook (Bruce C)持有股份：40.38M佔總股份比例：5.09%。
The Vanguard Group, Inc.持有股份：38.16M佔總股份比例：4.81%。
Hsiao (Jane H)持有股份：33.13M佔總股份比例：4.17%。
Frost Gamma Investments Trust持有股份：220.16M佔總股份比例：27.74%。
Rubric Capital Management LP持有股份：47.79M佔總股份比例：6.02%。
Holbrook (Bruce C)持有股份：40.38M佔總股份比例：5.09%。
The Vanguard Group, Inc.持有股份：38.16M佔總股份比例：4.81%。
Hsiao (Jane H)持有股份：33.13M佔總股份比例：4.17%。
OPKO Health Inc的前三大股東類型是什麼？
OPKO Health Inc 的前三大股東類型分別是：
Frost Gamma Investments Trust
Rubric Capital Management LP
Holbrook (Bruce C)
Frost Gamma Investments Trust
Rubric Capital Management LP
Holbrook (Bruce C)
有多少機構持有OPKO Health Inc(OPK)的股份？
截至2025Q3，共有457家機構持有OPKO Health Inc的股份，合計持有的股份價值約為208.31M，占公司總股份的27.13% 。與2025Q2相比，機構持股有所增加，增幅為-50.75%。
哪個業務部門對OPKO Health Inc的收入貢獻最大？
在FY2025Q2，Health Insurers業務部門對OPKO Health Inc的收入貢獻最大，創收58.48M，占總收入的57.84% 。
